Evidence map›Paper›PMID 34314468›Full record

ArticlePloS one2021

Use of fourth-generation rapid combined antigen and antibody diagnostic tests for the detection of acute HIV infection in a community centre for men who have sex with men, between 2016 and 2019.

Jorge Saz, Albert Dalmau-Bueno, Michael Meulbroek, Ferran Pujol, Josep Coll, Ángel Herraiz-Tomey, Félix Pérez, Giovanni Marazzi, Héctor Taboada, Dante R Culqui and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jorge SazProjecte dels NOMS-Hispanosida, Barcelona, Spain.ORCID 0000-0002-8679-634X
Albert Dalmau-BuenoBCN Checkpoint, Barcelona, Spain.
Michael MeulbroekProjecte dels NOMS-Hispanosida, Barcelona, Spain.
Ferran PujolProjecte dels NOMS-Hispanosida, Barcelona, Spain.
Josep CollIrsiCaixa AIDS Research Institute, Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
Ángel Herraiz-TomeyGrupo Pulso (a company of Evidenze Group), Sant Cugat del Vallés, Spain.
Félix PérezProjecte dels NOMS-Hispanosida, Barcelona, Spain.
Giovanni MarazziProjecte dels NOMS-Hispanosida, Barcelona, Spain.
Héctor TaboadaProjecte dels NOMS-Hispanosida, Barcelona, Spain.
Dante R CulquiGrupo Pulso (a company of Evidenze Group), Sant Cugat del Vallés, Spain.ORCID 0000-0003-1570-8012
Joan A CaylàTuberculosis Research Unit of Barcelona (UITB) Foundation, Barcelona, Spain.
BCN Checkpoint Working Group
Median SCP (Spain) · ESIrsiCaixa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the use of fourth-generation rapid diagnostic tests in identifying acute infection of Human Immunodeficiency Virus (HIV).

methodsBCN Checkpoint promotes sexual health among men who have sex with men (MSM), with a focus on diagnosing HIV early, initiating combined antiretroviral treatment (cART) promptly, and recommending regular repeat testing for those who have tested negative. This cross-sectional study included all test results obtained at the centre between 25 March 2016 and 24 March 2019. The Alere™ HIV Combo (now rebranded to Determine™ HIV Ultra, from Abbott) was used to detect p24 antigen (p24 Ag) and/or immunoglobulin M (IgM) and G (IgG) antibodies to HIV-1/HIV-2 (HIV Ab). Rapid polymerase chain reaction (PCR) confirmatory testing and Western blot (WB) were performed for clients with a positive rapid test result. Confirmed HIV cases were promptly referred to the HIV unit for care and cART prescription.

resultsA total of 12,961 clients attended BCN Checkpoint during the study and 27,298 rapid tests were performed. 450 tests were found to be reactive, of which 430 confirmed as HIV-positive, representing a prevalence of 3.32%. Four confirmed cases (0.93%) were detected as "p24 Ag only", nine (2.09%) as "both p24 and HIV Ab" and 417 (96.98%) as "HIV Ab only". The "p24 Ag only" group had a 1-log higher viral load than the other groups and initiated treatment on the following working day. Overall, there were 20 false-positive results (0.07% and 4.44% of total and reactive tests, respectively), of which 10 positive for "p24 Ag only" and 10 for "HIV Ab only".

conclusionsFour Acute HIV Infections (AHI), with very high viral loads, have been detected with the "p24 Ag only" while the HIV Ab were still absent. Referral to the HIV unit and initiation of cART on the following working day contributed to improving persons' health and to reduce HIV transmission chain.

Indexed as

AdultAnti-Retroviral AgentsCross-Sectional StudiesFalse Positive ReactionsHIV-1HIV AntibodiesHIV Core Protein p24HIV InfectionsHomosexuality, MaleHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedPoint-of-Care SystemsReagent Kits, DiagnosticAnti-Retroviral AgentsHIV AntibodiesHIV Core Protein p24Immunoglobulin GImmunoglobulin MReagent Kits, DiagnosticRNA, Viral

Identifiers

PMID34314468
PMCPMC8315512
OpenAlexW3186604311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.